| Assessment Status | Rapid Review Complete |
| HTA ID | 23060 |
| Drug | Somapacitan |
| Brand | Sogroya® |
| Indication | Somapacitan (Sogroya®) is indicated for the replacement of endogenous growth hormone in children aged three years and above and adolescents with growth failure due to growth hormone deficiency (GHD), and in adults with GHD. |
| Assessment Process | |
| Rapid review commissioned | 25/09/2023 |
| Rapid review completed | 27/11/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that somapacitan not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
